Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy

NCT03416374 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT03416374
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03416374 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy
Lead sponsor
Takeda
Phase
Phase 4
Overall status
Completed
Start date
February 18, 2018
Completion date
May 28, 2021
Enrollment
45 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed and/or refractory multiple myeloma